Revolutionizing Cancer Treatment: CAR-T Cell Therapy
Image Credit: Nemeth Laszlo/Shutterstock
CAR T-cell therapy represents a groundbreaking approach to cancer treatment by genetically engineering a patient’s immune cells to target and eliminate cancer cells. Despite its effectiveness, high costs have limited its availability worldwide. However, innovative techniques like 3D printing could enable the production of these engineered cells at a reduced cost and increased speed, enhancing accessibility to this vital treatment.
According to David Coe, who is affiliated with CoED Biosciences in Cardiff, England, “For critically ill patients, delays in receiving CAR T therapy can lead to deterioration in their condition during the long wait.”
The process of CAR T-cell therapy involves extracting T cells from a patient’s blood, genetically modifying them to recognize cancer antigens, and then expanding these cells in a lab environment. Traditionally, this involves activating the cells using beads and a harmless virus, which introduces the chimeric antigen receptor (CAR) gene into the T cells. Generally, 30 to 70 percent of T cells are successfully reprogrammed, with higher success rates linked to improved patient outcomes according to research.
This entire procedure takes about a month, and the costs can exceed £280,000 per treatment, making it primarily accessible to wealthier countries. Gillian Griffiths from the University of Cambridge, who was not involved in this recent study, highlights these concerns about availability and costs.
To overcome these challenges, Judith Guasch Camel and her team at the Barcelona Institute of Materials Science have developed a 3D printed gel that mimics the structure of human lymph nodes, where T cells are typically activated during immune responses. This model provides essential physical cues that support T cell activation and proliferation.
Historically, T cells have been activated on flat plastic surfaces, which lack the tactile feedback necessary for optimal interaction and proliferation. Guasch Camel presented these findings at the Biophysical Immunoengineering Conference hosted by the Royal Society in London.
In experiments, human T cells mixed with CAR-encoding virus and activation beads were placed into these lymph node-like structures. The results indicated that 75 percent of T cells proliferated successfully using this method, compared to only 50 percent with traditional approaches. This implies a reduction in the expensive materials required for CAR engineering, as noted by researcher Koh.
Furthermore, T cells in the new environment proliferated nearly twice as fast, potentially reducing labor costs and ensuring timely treatment for patients.
Such advancements signal progress toward democratizing access to CAR T-cell therapy globally, as Griffiths noted, “The goal is to develop immunotherapies that are accessible worldwide, even in low- and middle-income countries.” Comprehensive research is essential to assess the scalability and associated costs of this promising technique.
Topics:
The content has been rewritten to be SEO optimized while retaining the original HTML structure and incorporating relevant keywords for better visibility.
Source: www.newscientist.com
